Cell-Based Electrical Impedance Platform to Evaluate Zika Virus Inhibitors in Real Time
March 24th, 2023
3.4K views
Here, we demonstrate the use of cell-based electrical impedance (CEI) as a very easy and straightforward method to study Zika virus infection and replication in human cells in real time. Furthermore, the CEI assay is useful for the evaluation of antiviral compounds.
Overview
This study demonstrates the use of cell-based electrical impedance (CEI) to investigate Zika virus infection and replication in real time. The CEI assay also serves as a method for evaluating antiviral compounds.
Key Study Components
Area of Science
- Virology
- Cell Biology
- Antiviral Research
Background
- Viral infections often require real-time monitoring for accurate assessment.
- Traditional endpoint assays may overlook critical information.
- CEI allows for continuous observation of viral dynamics.
- This method can enhance the evaluation of antiviral efficacy.
Purpose of Study
- To showcase the CEI technique for studying Zika virus infection.
- To evaluate the effectiveness of antiviral compounds in real time.
- To analyze the infection kinetics of different cell types.
Methods Used
- Preparation of CEI plates with interdigitated electrodes.
- Seeding of A549 cells and monitoring their adherence.
- Administration of virus and antiviral compounds.
- Data collection and analysis using CEI software.
Main Results
- Infection kinetics varied significantly with cell type and MOI.
- CEI assays indicated the dependency of antiviral activity on compound concentration.
- IC50 values were determined for various compounds.
- CEI provided a non-invasive method to assess Zika virus replication.
Conclusions
- CEI is a powerful tool for real-time analysis of viral infections.
- The technique can effectively evaluate antiviral compounds.
- Further studies may enhance understanding of Zika virus dynamics.
Frequently Asked Questions
What is cell-based electrical impedance (CEI)?
CEI is a method that measures the electrical impedance of cells to monitor their behavior and responses in real time.
How does CEI help in studying viral infections?
CEI allows for continuous monitoring of viral infection dynamics, providing insights that traditional assays may miss.
What types of cells were used in this study?
A549 and U87 cells were utilized to assess their susceptibility to Zika virus infection.
What are IC50 values?
IC50 values indicate the concentration of a compound required to inhibit a biological process by 50%.
Can CEI be used for other viruses?
Yes, CEI can be adapted to study various viral infections beyond Zika virus.
Is CEI a non-invasive method?
Yes, CEI is a label-free and non-invasive technique for monitoring cell behavior.
Executive Industry Relevance
Cell-based electrical impedance (CEI) platforms enable real-time, label-free monitoring of viral cytopathogenicity and compound efficacy, addressing the limitations of traditional endpoint assays in antiviral discovery. This approach enhances predictive confidence in early-stage inhibitor evaluation by capturing dynamic infection kinetics and compound responses. Integrating CEI into the discovery pipeline supports risk-adjusted advancement and portfolio triage for antiviral candidates targeting Zika virus and similar pathogens.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Enables direct observation of viral cytopathic effects and compound action in live cell monolayers.
- Supports functional target validation by quantifying infection kinetics and inhibitor potency in real time.
- Facilitates mechanistic de-risking by distinguishing cell line and MOI-dependent infection profiles.
- Improves predictive confidence for advancing antiviral leads based on quantitative, time-resolved data.
Screening & Assay Development
- Provides a standardized, reproducible assay format for high-throughput antiviral screening.
- Generates quantitative outputs such as IC50 and CIT50 values for compound ranking.
- Enables label-free, non-invasive monitoring, reducing assay complexity and variability.
- Supports rapid assay adaptation to different cell types and viral strains.
Translational & Preclinical Research
- Aligns in vitro infection models with disease-relevant viral kinetics for translational continuity.
- Enables dynamic assessment of compound efficacy across multiple infection parameters.
- Supports risk-adjusted preclinical advancement by providing robust, quantitative efficacy data.
Pipeline & Workflow Integration
CEI platforms position within the early discovery to lead identification continuum, bridging hypothesis-driven target validation and quantitative screening for antiviral programs.
- Discovery Biology: Quantifies infection kinetics and compound effects, supporting hypothesis testing and biological de-risking.
- Screening: Delivers reproducible, quantitative readouts (IC50, CIT50) for compound evaluation and prioritization.
- Analytics: Provides time-resolved impedance profiles and statistical outputs for comparative analysis.
- Translational Research: Enables alignment of in vitro findings with disease-relevant viral dynamics.
- Enterprise Reuse: Offers a scalable, adaptable platform for ongoing antiviral and cytopathogenicity studies.
Operational & Enterprise Impact
- Scientific Value: Enhances predictive confidence and target validation by capturing real-time infection and inhibition dynamics.
- Operational Value: Increases standardization, reproducibility, and scalability in antiviral screening workflows.
- Strategic Value: Supports informed go/no-go decisions and capital-efficient portfolio management.
- Portfolio Impact: Enables risk-adjusted prioritization and advancement of antiviral candidates.
Implementation Considerations
- Requires expertise in cell culture, virology, and impedance-based assay operation.
- Needs access to CEI instrumentation and compatible analytical software.
- Demands cross-team standardization of cell lines, MOI, and assay conditions.
- Adaptable to various cell types and viral strains with protocol optimization.
- Dependent on careful control of seeding density and infection parameters to ensure data quality.
Biopharma FAQs
Why does null hypothesis testing matter for CEI-based Zika inhibitor validation?
Null hypothesis testing in CEI assays ensures that observed impedance changes are statistically attributable to compound effects rather than random variation. This rigor supports confident target validation and reduces false positives in antiviral discovery pipelines.
How does independent variable isolation fit CEI antiviral screening?
Isolating variables such as cell type, MOI, and compound concentration in CEI assays enables precise attribution of observed effects, supporting robust mechanistic de-risking and reproducible screening outcomes.
What do quantitative impedance measurements enable in antiviral evaluation?
Quantitative impedance data provide real-time profiles of infection kinetics and compound efficacy, enabling calculation of IC50 and CIT50 values for informed compound ranking and advancement decisions.
Why are replication requirements critical for CEI assay collaboration?
Replication across wells and experiments ensures assay reproducibility and data reliability, facilitating cross-functional collaboration and confidence in advancing antiviral candidates.
What statistical analysis capabilities are needed before CEI implementation?
Robust statistical tools are required to analyze impedance curves, calculate IC50/CIT50, and compare conditions, ensuring that data-driven decisions support portfolio advancement and risk management.
Chapters in this video
0:04
Introduction
0:40
Cell‐Based Electrical Impedance (CEI) Plate Preparation, Cell Seeding, and CEI Assay
2:12
Antiviral Compound Preparation and Virus Infection
3:28
Data Analysis
3:57
Results: Effect of Antiviral Compound and Zika Virus Replication on CEI Profiles
5:22
Conclusion
